Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,641,270
-$31,628,291 QoQ
Shares Held
219,334
-88.7% QoQ
Ownership
0.137%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Alyeska Investment Group, L.P. holds $989,063,778 across 83 Biotechnology names. DNLI ranks #37 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
659,279 | $123,469,771 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
1,417,916 | $112,426,559 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
889,298 | $109,010,148 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
697,692 | $42,112,689 | |
| 5 | MRNA |
Moderna, Inc.
|
560,819 | $39,274,154 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
276,455 | $31,701,094 | |
| 7 | LBRX |
Lb Pharmaceuticals Inc
|
863,947 | $28,039,399 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
80,846 | $27,066,432 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,641,270 | 219,334 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $37,269,561 | 1,941,123 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,183,873 | 859,108 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||